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incurable metastatic stage (5) . Autoantibody levels in patient blood serum have been proposed as diagnostic biomarkers for early stage diagnosis of cancers, since an increase in serum levels of certain autoantibodies has been shown to precede the development of disease symptoms (6, 7) and correlate with cancer incidence (8) for cancers of the breast (9) , lung and small-cell lung (10, 11) , colon (12) , ovary (13) prostate (14) and head and neck cancer (15, 16) .
Theories of the process of autoantibody production in cancer are complex and not yet fully understood. The immune response towards tumour-associated antigens (TAAs) presented in early stages of carcinogenesis, is thought to occur in response to cancer immunosurveillance, the process by which the immune system recognizes and destroys invading pathogens as well as host cells that have become cancerous (17) (18) (19) . It has also been suggested that genetic, hormonal and environmental influences may play a part in triggering autoimmunity.
Immunologic processes causing autoantibody production are believed to be generated by the immune system in response to mutations, degradation, over-expression of proteins and/or the release of proteins from damaged tissue (20) (21) (22) (23) . Autoantibody production is also believed to be caused by mis-presentation or mis-folding of proteins which may be recognized by the immune system leading to autoantibody production and therefore, tumour-associated antigens (TAAs) or proteins that have undergone alternate post-translational modifications (PTMs) may be recognised as non-autologous (17, 19, 24) , i.e.: their phosphorylation, glycosylation, oxidation or proteolytic cleavage could generate a neo-epitope or enhance self-epitope presentation and affinity to the major histocompatibility complex or T-cell receptor, inducing an immune response (25) . A neo-epitope is an epitope which is located within an unexposed region of the protein, preventing any interaction between the molecule and antibodies or lymphocytes, therefore avoiding the induction of an immune response against the molecule. range of cancers of various stages of malignancies in different cell types including bladder, breast, cervical, colon, esophageal, gastric, liver, lung, ovarian, prostate, pancreatic, renal, small bowel, rectal, adenocystic carcinomas, melanoma, sarcoma, thyoma, liposarcoma and leiomyosarcoma compared to healthy controls. Blood ECPKA levels are increased and ECPKA levels decreased after surgical removal of solid tumours (35) . With the assumption that this excretion results in the production of anti-ECPKA antibodies, an enzyme immunoassay measuring the IgG of this autoantibody was developed and the sensitivity and specificity of this biomarker for detecting the incidence of 20 different cancers was calculated to be 90% and 87%. Anti-ECPKA autoantibody was detected in 90% of the patient samples and in only 13% of the control samples, indicating that the presence of the ECPKA autoantibody in sera correlates with cancer incidence (8) ..Furthermore, autoantibodies are easily extracted from blood serum and are generally stable and bind with high specificity to their specific antigenic proteins (36) .
To date, no single autoantibody biomarker has been utilised as a cancer biomarker due to the low sensitivity and specificity of single markers. . Panels of multiple tumour-associated autoantibodies with high specificity and sensitivity are sought therefore for translation into simple biomarker panel tests for routine clinical diagnosis of early-stage cancer. (17, 19, (37) (38) (39) (40) ).
3) Methodology of autoantibody detection
To advance the discovery of novel combinations of autoantibody biomarkers, techniques which allow the simultaneous screening of multiple biomarkers are required. Examples of such methodologies include serological analysis of tumour antigens by recombinant cDNA expression cloning (SEREX), phage display, serological proteome analysis (SERPA), multiple affinity protein profiling (MAPPing) or protein microarrays. Please refer to figure 1 and table 1 for a comprehensive overview and comparison of methodologies and associated processes used to detect multiple autoantibodies simultaneously.
Serological analysis of tumour antigens by recombinant cDNA expression cloning (SEREX)
SEREX, the serological analysis of tumour antigens by recombinant cDNA expression cloning, was first developed in 1995 (41, 42) . This technique utilises antibody reactivity with autologous cancer patient sera to identify immunogenic tumour proteins (17, 39) . The cDNA expression library utilised in this methodology is constructed from tumour specimens of interest and then cloned into λ-phage expression vectors which are used to transfect Escherichia coli. The resulting recombinant proteins are then transferred onto a nitrocellulose membrane which is incubated with diluted patient sera. Clones which are reactive with hightiter IgG antibodies are identified using an enzyme conjugated secondary antibody specific for human IgG. The cDNA clone is sequenced and the autoantigen identified. The major advantage of using SEREX is the fact that it allows the identification of tumour-associated antigens from in vivo material. Another advantage of this technology is that it allows the identification of several tumour-specific antigens in one experiment. Furthermore, both the tumour-specific antigen and it's coding cDNA are present in the same plaque when immunoscreening is performed which allows the subsequent sequencing of matched cDNA immediately. The disadvantage of SEREX is the high likelihood of false-positive results.
Secondly, the use of tumour tissue from a single cancer patient followed by screening with autologous patient sera limits identification of tumour-associated antigens to that patient.
Moreover, this complex methodology does not detect alternate tumour-associated posttranslational modifications of antigens (17) . Patients may also exhibit autoimmunity to autologous proteins and therefore irrelevant non-cancer-associated proteins may be detected.
Furthermore, parallel analysis with healthy donor sera as controls cannot be performed easily. 
Phage display
Alternatively, a cDNA phage display library is constructed directly from tumour tissue or a cancer cell line derived from patient tumour material (43). Phage clones which bind to cancer sera are identified through a differential biopanning approach (44). Alternatively, a more costeffective method is to construct the cDNA phage display library by expressing the phage proteins fused to the antigens on the surface of bacteriophages. The phage display method has the advantage of allowing the simultaneous screening of a large number of antigens against the sera of cancer patients relative to serum of healthy individuals (14, 43) . The phage-display method has a higher throughput value than the SEREX method but again, antigens with alternate post-translational modifications cannot be detected using the phage-display method (19, 45) .
Protein microarray
The protein array methods are advantageous in that they require only minute amounts of patient sera (46) while enabling the simultaneous screening of large numbers of antigens in a single test (47) (48) (49) (50) (51) (52) . In this methodology, purified or recombinant as well as synthetic proteins are used. Alternatively, fractured proteins of tumour origin are spotted onto the microarray platform. Arrays are then incubated with patient and control sera (17, 19, 53, 54) . The array platform can be either two dimensional (such as nitrocellulose membranes, microtitre plates or glass slides) or three dimensional (such as nanoparticles or beads). While protein microarray methods are commonly used to analyse recombinant proteins expressed from Escherichia coli cells, alternatively, other host expression systems such as yeast and insect cells have been used to produce libraries presenting proteins with the correct posttranslational modifications. The disadvantage associated with this method is the requirement for high quality protein synthesis (55) . Furthermore, studies utilising protein microarrays are time restricted due to the short shelf-life of protein arrays (19, 56) .
Reverse-capture microarray
In this method, the antibodies reacting with specific proteins are spotted onto the microarray.
Similar to the protein microarray, the reverse-capture microarray is incubated with tumour lysate and serum proteins and the microarrays with captured proteins are then further incubated with sera from patients and controls. The autoantibodies are detected with fluorescent-labelled secondary antibody (57) (58) (59) . The advantage of the utilisation of "reversecapture" microarray technology is the elimination of the need for recombinant proteins and allows the instant identification of cancer-specific autoantibodies. However, only known antigens and their commercially available antibodies can be analysed and immunoreactivity with post-translationally modified antigens cannot be differentiated unless antibodies which bind exclusively to these antigens are commercially available.
Serological proteome analysis (SERPA)
Serological proteome analysis (SERPA) (60) is also known as PROTEOMEX. This technique is very useful for detection of tumour-associated antigens since it incorporates an effective separation of a complex mixture of proteins based on their isoelectric points and molecular weights through 2D electrophoresis and western blotting followed by identification by mass spectrometry (19, 61, 62) . Proteins from the tumour tissue of interest are transferred onto a nitrocellulose membrane and immobilised. The sera from cancer patients and controls are separately screened using the immobilised proteins. The appropriate immunoreactive profiles are compared and the cancer-associated antigenic spots are identified by mass spectrometry.
Similar to the SEREX technique, the advantage of the SERPA technique is the use of in vivo derived tumour-associated antigens. Furthermore, the SERPA technique allows for the identification of tumour-specific post-translational modifications and isoforms but is limited in terms of the identification of low-abundance and transmembrane tumour-associated antigens (17, 34, 51 healthy donor sera as controls and avoids the time-consuming construction of cDNA libraries, enabling this methodology to be completed within a few hours compared to several days for SEREX and phage-display technology. However, due to the way that western blots are prepared, SERPA can only be used to detect linear epitopes (63) .
Multiple affinity protein profiling (MAPPing)
The MAPPing methodology incorporates 2D immunoaffinity chromatography which is followed by the identification of tumour-associated antigens by tandem mass spectrometry analysis (64) . In the first phase of the initial immunoaffinity chromatography, lysate from cancer cell lines or tumour tissue containing nonspecific tumour-associated antigens is bound to IgG that was obtained from healthy controls in an immunoaffinity column. The flowthrough fraction is then subjected to 2D immunoaffinity in a column that contains IgG from cancer patients and columns can be utilised in parallel (65) . The tumour antigens which are captured in the patient columns are eluted and digested for identification by nano-liquid chromatography mass spectrometry. MAPPing ensures that the tumour antigens are maintained in a solution which allows the potential identification of structural epitopes. The disadvantages associated with this method include the restriction of the tumour antigen identification to antibody interactions with a low dissociation rate constant. Furthermore, immunoprecipitation using these affinity columns limits the detection of tumour antigens in more complex protein solutions, such as cell lysate. 
4) Currently utilised diagnostic autoantibody cancer biomarkers

4.1) Prostate cancer
The prostate-specific antigen (PSA), also known as kallikrein 3 (KLK3), is part of a family of proteases which are known as kallikreins. These proteases are encoded by a cluster of genes which are located within a 300 kb region on chromosome 19q13.4 (67) . PSA is responsible for the cleavage of the proteins seminogelin I and II, which leads to the liquefaction of the semen in seminal fluid (68) . PSA activity is normally confined to prostatic glandular structures only, however disturbances of this structure such as by formation of a tumour, may result in leakages of PSA into the circulatory system (69) . The PSA blood test measures the amount of PSA within a patient's circulation. Any PSA level between 0-4 (ng/ml) is considered normal, while PSA levels between 4-10 (ng/ml) are slightly elevated, PSA levels between 10-20 (ng/ml) are moderately elevated and any PSA levels above 20 (ng/ml) are highly elevated. A positive PSA serum level above 4 (ng/ml) concentration has diagnostic potential in prostate cancer patients (70) .
Although PSA serum levels are the most commonly utilised diagnostic test for this cancer to date, it's specificity is less than fifty percent, resulting in frequent false positive results (71) .
The primary limitation of the use of PSA as a diagnostic biomarker is the inability to distinguish between benign and malignant stages of the disease (72) . Increased PSA serum levels may also arise due to non-cancerous conditions such as enlargement of the prostate, (SSX-2,4), X antigen family member 1B (XAGE-1b), lens epithelium-derived growth factor (LEDGF), transferrin receptor protein 9 (p90) and alpha-methylacyl-CoA racemase (AMACR). The platform allowed the simultaneous screening of these six autoantibodies alongside PSA and PSA screening alone in 131 pre-surgery biopsy confirmed prostate cancer patients and 121 prostatitis and/or benign prostatic hyperplasia patients. The overall aim of this research was to develop a reliable platform which will enable the diagnosis of prostate cancer patients relative to non-malignant cases. Xie et al. (73) found that PSA alone had a sensitivity of 52% and Specificity of 79% in all patients while the A+PSA platforms showed a sensitivity of 79% and a specificity of 84% in all patients. The A+PSA platform also had a decreased false positive outcome of only 16% versus 21% when PSA alone was utilised.
Overall, the accuracy of the A+PSA test platform was as high as 81% while PSA alone only showed an accuracy of 65%. Wang et al., (14) utilised phage protein microarray technology and 119 prostate cancer patient sera and 138 healthy control sera, to identify increased autoantibody levels of bromodomain-containing protein 2 (BRD2), eukaryotic translation initiation factor 4 gamma 1 (eIF4G1), ribosomal protein L22 (RPL22), ribosomal protein LBa (RPL13a), and hypothetical protein XP_373908 (XP_373908) as the antigens most frequently bound to auto-antibodies in prostate cancer patient serum. This microarray displayed 81.6% sensitivity and 88.2% specificity. Except for hypothetical protein XP_373908, these structures are derived from intracellular proteins involved in regulating either transcription or translation and closely resembled autologous proteins. However, when tested, their DNA sequences were not identical to those of genes encoding for autologous proteins (14) . Moreover, the undergone prostatectomy and in 3 of 11 serum samples from patients with hormone-refractory disease, suggesting that the autoantibody profile is attenuated on removal of the "immunogen" or after treatment with anti-androgen chemotherapeutic agents, or both. Taken together these results provide evidence that the above mentioned autoantibodies are associated with the presence of this cancer (14) . A more recent microarray study, which aimed to identify an autoantibody signature to distinguish prostate cancer from benign prostatic hyperplasia in patients who showed increased PSA levels, displayed a sensitivity of 95% and 80% specificity compared to 12.2% sensitivity and 80% specificity of PSA alone. This microarray, 
4.2) Breast cancer
Biomarkers such as carcinoma antigen 15-3 (CA 15-3), carcinoma antigen 27-29 (CA [27] [28] [29] and carcinoembryonic antigen (CEA) have been accepted for clinical use; however, due to their low sensitivity and specificity they are suggested to be utilised for the diagnosis of more advanced stages rather than for the early diagnosis of breast cancer (75) . In terms of autoantibody biomarkers, antibodies to human epidermal growth factor receptor 2 (HER2) (76) , tumour protein 53 (p53) (77), Mucin 1, cell surface associated (MUC1) (78) and NY-ESO-1 (79) were first discovered in breast cancer patients. In fact, antibodies to HER2/neu (76) have been detected in early stage breast cancer patients but their presence has also been detected in other cancers, limiting their use as a diagnostic biomarker for breast cancer alone (28, 30, 80 ). An increase to 44% sensitivity and 97.6% specificity in breast cancer detection was achieved through the successive addition of the three tumour-associated antigens p53, (84) with a cohort of 94 healthy controls, 97 primary breast cancer sera and 40 ductal Carcinoma in Situ (DCIS) sera, tested for seven antigens including HER2, c-myc, p53, breast cancer type 1 susceptibility protein (BRCA1), breast cancer type 2 susceptibility protein (BRCA2), Ny-ESO-1 and MUC1. The specificity of the assay was found to be as high as 91-98%, even when tested for individual markers only; however, the individual autoantigen assay sensitivity was only 3-23% in the DCIS sera and 8-24% in the primary breast cancer sera. On comparison, the sensitivity increased to 45% in DCIS sera and 64% in primary cancer sera with a specificity of 85% when a combined panel of 6 out of the 7 autoantigens was tested; which, alongside other cancer detection methods such as mammography, may lead to a significant improvement in breast cancer detection. A study by Hamrita et al. (85) utilised the SERPA method to test sera from patients with more invasive breast cancer. The study found HSP60 autoantibodies in 47.5% of breast cancer patients and in only 4.7% of healthy control sera. Alpha-2-HS-glycoprotein (AHSG) autoantibodies have also been identified in 79.1% of 81 breast cancer patient samples and only in 9.6% of 73 control samples; however, the diagnostic relevance of these autoantibodies remain to be validated (80) . 
4.3) Lung cancer
Lung cancer is notoriously heterogeneous and therefore no diagnostic test for the early detection of this cancer has been established (86) .
A study by Pereira-Faca et al. (87) used one-and two-dimensional electrophoresis as well as western blotting and mass spectrometry to identify the 14-3-3 Θ theta (14-3-3 Θ) autoantibody as a potential biomarker for the early-stage diagnosis of lung cancer in a cohort consisting of 45 newly diagnosed lung cancer patients, 18 pre-diagnostic lung cancer patients and 62 matched healthy controls. This 14-3-3 Θ autoantibody was tested in a panel alongside autoantibodies to PGP 9.5 and annexin I, and together these displayed a sensitivity of 55% and specificity of 95%. Furthermore, reactivity to laminin receptor 1 (LAMR1) has also shown high reactivity to lung cancer patient sera (88) . This protein microarray study by Qiu et al. tested 85 pre-diagnostic lung cancer patients and 85 matched healthy controls against 14-3-3 Θ, LAMR1 and annexin I and achieved a sensitivity of 51% and a specificity of 82% (88). 
4.4) Colon cancer
To date, CEA is the only serological biomarker in clinical use for the diagnosis of colorectal cancer; however, this biomarker is also hindered by its low specificity and sensitivity (92) . A study by Liu et al. (92) showed an increase in colon cancer detection sensitivity over CEA when an ELISA based mini-array containing five tumour-associated antigens, IMP dehydrogenase 1 (Imp1), nucleoporin p62 (p62), K homology domain containing protein over expressed in cancer (Koc), p53 and c-myc, were used. When 46 colon cancer patients and 58 healthy controls were probed with the above mentioned mini-array, the sensitivity for the combined panel was 82.6% and its specificity was 89.7% in the colon cancer patients (92) . 
positive disease status and thus the search for colon cancer biomarkers is still ongoing.
Another marker called Mucin-5AC (MUC5AC), was investigated in order to increase sensitivity of colon cancer detection. This ELISA-based experiment was performed on 20 patients with colorectal polyps, 30 colorectal cancer patients and 22 healthy volunteers and it's sensitivity was found to be 54%, however this marker exhibited a much lower specificity than Fas of 73% (94) .
Studies have shown that autoantibodies to p53 can help identify individuals at increased risk of developing colorectal cancer since these autoantibodies have been detected in patients with precancerous colorectal cancer lesions. In fact, the screening for these autoantibodies is suggested in addition to colonoscopy screens (95) (96) (97) . However, antibodies to p53 have also been associated with a range of other cancers, which reduces the specificity of this biomarker for colon cancer.
Another study by He et al. (98) has shown increased levels of autoantibodies to HSP60 in the sera of 13 out of 25 colorectal cancer patients relative to 1 out of 15 healthy volunteer sera which results in 52% sensitivity and 93.3% specificity of this marker for colon cancer diagnosis; however, the same autoantibodies have also been observed in breast cancer patients which demonstrates that this biomarker is not specific to colon cancer alone (98 
when Calnuc was added to a tumour-associated antigen panel comprised of c-myc, p53, G2/mitotic-specific cyclin-B1 (CCNB1) and G1/S-specific cyclin-D1 (CCND1) (99).
4.5) Stomach cancer
To date, there are no stomach cancer specific biomarkers although p53 autoantibodies have been identified as being associated with stomach cancer as well as several other cancers (100, 
4.6) Liver cancer
Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is diagnosed by the histological examination of the liver using ultrasonography (103). Although this technology displays a sensitivity of 60-80%, a positive predictive value of 78% and a specificity of up to 98% (104), it is nonetheless subject to detection bias as it is an operatordependent technology and small tumours may be overlooked against a cirrhotic background (105, 106). Therefore, there is a need to support the diagnosis of this cancer on a more molecular level. The search for autoantibodies for the diagnosis of the cancer is therefore of great interest in order to develop a blood test for HCC diagnosis.
Alpha-fetoprotein (AFP), a normal serum protein synthesised during embryonic development, is currently considered to be the best biomarker available for HCC diagnosis (107) . Elevated levels of AFP are observed in pregnant woman and chronic liver disease patients; however, lower levels of this biomarker are also observed in healthy individuals and non-pregnant woman, implying that AFP cannot be utilised for the diagnosis of small HCC tumours (108) . their ELISA-based test. AFP levels <20ng/ml were considered normal, while 21-400ng/ml was defined as elevated and >400 ng/ml were considered as diagnostically significant. With regards to these levels, the group confirmed the low sensitivity of AFP as 54% and did not recommend this marker for utilisation in the routine diagnosis of HCC (109) . Serum levels of des-gamma-carboxyprothrombin (DCP), another potential biomarker for HCC diagnosis have been compared to AFP levels in an ELISA-based experiment performed by Marrero et al. (111) . This research tested sera from 48 healthy controls, 51 patients with noncirrhotic hepatitis, 53 patients with compensated cirrhosis and 55 patients with hepatocellular carcinoma against DCP and AFP individually and in combination in order to find the best marker or panel to differentiate hepatocellular carcinoma patients from other non-malignant chronic liver disease patients. The study concluded that the sensitivity and specificity of AFP levels alone are 77% and 73%, and of DCP 89% and 95% respectively and the combination of the two markers resulted in 88% and 95% sensitivity and specificity (111) . indicating that routine use of GAPDH for HCC diagnosis is not recommended while high HSP70 levels were detected in 46.7% of patients and in only 10% of controls. (113) . In the same study, high serological autoantibody levels of MnSOD were detected in 40% of patient sera and in only 10% of controls while high PRX autoantibody levels were detected in 33.3% of patients and 0% of controls (113) . 
